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SUPPLEMENTARY NOTES
ABSTRACT
PPARδ is a member of peroxisome proliferators activated receptors which play important role in regulating cellular metabolisms. Basal-like breast cancers accounting for ~15% of all breast cancer cases tend to be very aggressive and have poor prognosis. Basal-like breast cancers are considered to be derived from mammary stem cells. Abnormal activation of Wnt signaling is often found in human basal-like breast cancers. Here we report that PPARδ expression is induced by Wnt signaling in mammary stem cells. Activation of PPARδ by its ligands and fatty acids promotes the proliferation of mammary stem cells. The proliferation of mammary cancer stem cells is stimulated by PPARδ agonists. Activation of PPARδ promotes while its inhibition suppresses the tumorigenesis of MMTV-Wnt1 transgenic mice. We also found that PPARδ antagonist inhibits the proliferation and anchorage-independent growth of a human basal-like breast cancer cell line. (Fig. 1b) . As the level of PPARδ mRNA in NIH3T3 cells expressing Wnt1 was si milar to t hat in cont rol NIH3T3 cells (data not shown), this result indicated that PPARδ expression is induced in mammary stem cells by Wnt signaling.
SUBJECT TERMS
Activation of PPARδ induces the proliferation of mammary stem cells. When cultured in suspension,
individual mammary stem cells form mammospheres, which are composed of myoepithelial cells, luminal epithelial cells, and stem cells. We found that the nu mber and siz e of primary mammospheres were not affected by the treatment of PPARδ agonist GW0742 or antagonist GSK0660. However, the number of secondary mammospheres was increased with the treatment of PPARδ agonist and decreased by PPARδ antagonist (Fig. 2) , suggesting that activation of PPARδ induces the proliferation of mammary stem cells.
Arachidonic acid is more potent in inducing mammary stem cell proliferation than GW0742. As fatty acids act as agonists for PPARδ, we examined if fatty acids could also promote proliferation of mammary stem cells. When mammary epithelial cells were treated with arachidonic acid, even more secondary mammospheres were produced compared with those treated with GW0742 (Fig. 3a) . Transient transfection assay revealed that while antagonist GSK0660 completely blocks the transactivation of PPARδ by GW0742, it only partially blocks PPARδ activity induced by arachidonic acid (Fig. 3b) . PPARδ carries activation domain 1 (AF1) which unlike AF2 can not be inhibited by an antagonist. Therefore, we tested the effect of arachidonic acid on the activity of AF1. Arachidonic acid was found to potentiate the AF1 transcriptional activity (Fig. 3c) . Saturated fatty acid palmitic acid (C16) is a weak activator of PPARδ. Palmitic acid tu rns out to be a we ak inducer for mammary stem cell proliferation (Fig. 3d) . (Fig. 4) .
Task 2. Evaluate the function of PPARD in triple-negative breast cancer mouse model.
Activation of PPARδ promotes while its inhibition suppresses the tumorigenesis of MMTV-Wnt1 transgenic mice.
Tumors from MMTV-Wnt1 transgenic mice most li kely originate from the expansion and transformation of mammary stem cells. Given that activation of PPARδ promotes the proliferation of mammary stem cells, we treated MMTV-Wnt1 mice with PPARδ agonist GW0742, antagonist GSK0660, or control vehicle (20 mice for each group). GW0742 promoted while GSK0660 inhibited the development of mammary tumors (Fig.  5) . The histology of the tumors from GW0742 or GSK0660-treated mice and control mice was similar (data not shown). Because of the strong oncogenic effect of Wnt1, the effects of PPARδ ligands on tumor development are relatively modest. However, for human breast cancers taking decades to develop, the impact of PPARδ activation by fatty acids from high fat diets could be far stronger. (Fig.  7A) . Furthermore, the anchorage-independent growth of HCC1937 cells was strongly inhibited by GSK0660 (Fig.  7B) . Similar results were obtained from another cell line BT20.
Methodologies. Mammary stem * We also found that PPARδ antagonist inhibits the proliferation and anchorage-independent growth of a human basal-like breast cancer cell line.
CONCLUSIONS
We report that PPARδ expression is induced by Wnt signaling in mammary stem/bi-progenitor cells. Activation of PPARδ by its ligands and fatty acids promotes the proliferation of mammary stem/bi-progenitor cells. Arachidonic acid is more potent by potentiating both the N-terminal activation function AF1 and the ligand-induced activation function AF2 of PPARδ. Saturated fatty acid palmitic acid (C16), a weak activator of PPARδ, was f ound to be a weak inducer for mammary stem cell proli feration. Activation of PP ARδ induces the proliferation of mammary cancer stem cells. Activation of PPARδ promotes while its inhibition suppresses the tumorigenesis of MMTV-Wnt1 transgenic mice. We also found that PPARδ antagonist inhibits the proliferation and anchorage-independent growth of a human basal-like breast cancer cell line.
